Compass Pathways plc, a biotechnology company focused on mental health innovations, has announced the publication of results from an open-label Phase 2 study in the Journal of Psychopharmacology. The study evaluated the safety and tolerability of a single 25 mg dose of COMP360 synthetic psilocybin in 22 patients with post-traumatic stress disorder (PTSD). Results, initially disclosed in May 2024, indicate that the treatment was well tolerated with no serious adverse events. Participants experienced rapid and durable symptom improvement observed up to 12 weeks post-administration. Common adverse events included headache, nausea, crying, fatigue, and visual hallucinations. The study showed significant reductions in CAPS-5 and Sheehan Disability Scale scores, suggesting functional improvement and symptom relief. Compass Pathways is finalizing designs for late-stage clinical trials to further explore COMP360's potential for PTSD treatment.